NVS - EMA advisors recommend many new meds at latest meeting
2023-09-15 11:05:45 ET
More on Lilly, Ascendis, and Novartis
- Eli Lilly: A Potential Game Changer For Weight Management And Cardiovascular Health
- Ascendis Pharma: Revenue Promise Meets Cash Flow Challenge
- Sandoz to commercialize biosimilar to J&J blockbuster drug Stelara
- Sell Eli Lilly And Buy This Coiled-Spring Dividend Aristocrat Instead
- Ascendis wins EU backing for hormone replacement therapy
For further details see:
EMA advisors recommend many new meds at latest meeting